XSense™ system's innovative cryogenic connector
technology designed to improve safety and maintain the integrity of
cryogen used in the cryoablation procedure
CAESAREA, Israel, Jan. 3, 2025
/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure",
"IceCure Medical" or the "Company"), developer of
minimally-invasive cryoablation technology that destroys tumors by
freezing as an alternative to surgical tumor removal, today
announced it has received an Intention to Grant Notice from the European Patent Office for
its invention titled "Cryogenic System Connector". This invention
was recently granted a patent in the
United States.
"We are experiencing increased momentum in the growth of our
intellectual property assets, further demonstrating our global
leadership in cryoablation. Europe
is a major market for us, with several key distributors selling
ProSense® and numerous new and ongoing independent clinical
studies initiated by doctors who are using our cryoablation
technology across many indications," stated IceCure's CEO,
Eyal Shamir.
XSense™ and its cryoprobes, which have U.S. Food and Drug
Administration clearance for all of the indications for which
IceCure's flagship ProSense® has already received clearance,
has the potential to address additional indications and significant
unmet needs in the global tumor ablation market, estimated at $1.67
billion in 2023 according to Grand View Research.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced
liquid-nitrogen-based cryoablation therapy systems for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The Company's flagship ProSense® system
is marketed and sold worldwide for the indications cleared and
approved to date including in the U.S., Europe and China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statements in this press release when it discusses the
belief that the Intention to Grant
Notice from the European Patent Office will increase
momentum in the growth of its intellectual property assets, its
global leadership in cryoablation and its new and ongoing
independent clinical studies, and the belief that the Intention to
Grant to Notice will support and accelerate the market adoption of
ProSense®. Important factors that could cause actual results,
developments and business decisions to differ materially from those
anticipated in these forward-looking statements include, among
others: the Company's planned level of revenues and capital
expenditures; the Company's available cash and its ability to
obtain additional funding; the Company's ability to market and sell
its products; legal and regulatory developments in the United States and other countries; the
Company's ability to maintain its relationships with suppliers,
distributors and other partners; the Company's ability to maintain
or protect the validity of its patents and other intellectual
property; the Company's ability to expose and educate medical
professionals about its products; political, economic and military
instability in the Middle East,
specifically in Israel; as well as
those factors set forth in the Risk Factors section of the
Company's Annual Report on Form 20-F for the year ended
December 31, 2023 filed with the SEC
on April 3, 2024, and other documents
filed with or furnished to the SEC which are available on the SEC's
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/european-patent-office-issues-intention-to-grant-notice-to-icecure-for-its-next-generation-cryoablation-technology-302341812.html
SOURCE IceCure Medical
